Public Employees Retirement System of Ohio continued to hold its position in shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,276 shares of the biopharmaceutical company’s stock at the close of the second quarter. Public Employees Retirement System of Ohio owned 0.09% of Intra-Cellular Therapies worth $475,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. SG Americas Securities LLC bought a new position in shares of Intra-Cellular Therapies during the second quarter worth about $103,000. Bank of America Corp DE raised its position in shares of Intra-Cellular Therapies by 53.4% during the first quarter. Bank of America Corp DE now owns 9,660 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 3,363 shares during the last quarter. Fred Alger Management Inc. bought a new position in shares of Intra-Cellular Therapies during the second quarter worth about $161,000. Voya Investment Management LLC raised its position in shares of Intra-Cellular Therapies by 16.0% during the second quarter. Voya Investment Management LLC now owns 16,911 shares of the biopharmaceutical company’s stock worth $210,000 after acquiring an additional 2,338 shares during the last quarter. Finally, Citigroup Inc. raised its position in shares of Intra-Cellular Therapies by 32.8% during the second quarter. Citigroup Inc. now owns 17,395 shares of the biopharmaceutical company’s stock worth $216,000 after acquiring an additional 4,295 shares during the last quarter. Institutional investors own 59.55% of the company’s stock.

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 18,750 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $15.75, for a total value of $295,312.50. Following the completion of the sale, the chief executive officer now owns 1,107,457 shares of the company’s stock, valued at $17,442,447.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Alafi Capital Co Llc acquired 258,065 shares of Intra-Cellular Therapies stock in a transaction on Monday, October 2nd. The stock was purchased at an average cost of $15.50 per share, with a total value of $4,000,007.50. Following the purchase, the insider now directly owns 3,953,270 shares of the company’s stock, valued at approximately $61,275,685. The disclosure for this purchase can be found here. Company insiders own 21.00% of the company’s stock.

A number of brokerages have recently issued reports on ITCI. Piper Jaffray Companies set a $10.00 price objective on Intra-Cellular Therapies and gave the stock a “hold” rating in a research report on Thursday, August 10th. SunTrust Banks, Inc. upgraded Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research report on Wednesday, November 8th. Cantor Fitzgerald restated a “buy” rating on shares of Intra-Cellular Therapies in a research report on Wednesday, August 9th. BidaskClub downgraded Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Finally, Zacks Investment Research downgraded Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $25.00.

Shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) opened at $14.79 on Monday. Intra-Cellular Therapies Inc. has a 1-year low of $7.85 and a 1-year high of $22.67.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.53). The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.06 million. Intra-Cellular Therapies had a negative return on equity of 27.40% and a negative net margin of 28,038.35%. The firm’s revenue for the quarter was up 675.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.70) earnings per share. analysts anticipate that Intra-Cellular Therapies Inc. will post -2.16 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/13/intra-cellular-therapies-inc-itci-position-held-by-public-employees-retirement-system-of-ohio.html.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies Inc. (NASDAQ:ITCI).

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.